Alkermes plc is a biopharmaceutical company focused on neuroscience, with commercial medicines for alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Its business combines proprietary branded products with manufacturing and royalty revenue from partnered products developed under license. The company is headquartered in Ireland, with a corporate office and R&D center in Massachusetts and a manufacturing facility in Ohio. In 2026 it expanded its commercial portfolio by acquiring Avadel Pharmaceuticals and adding LUMRYZ, a narcolepsy treatment, to its marketed products.
19,0 %
86,7 %
16,4 %
−5,2 %
3.55
3.19
| % | |
|---|---|
| Proprietary commercial products | 70% Branded medicines that Alkermes markets and sells itself, including treatments for schizophrenia, bipolar I disorder, alcohol dependence, opioid dependence and narcolepsy. |
| Manufacturing revenue | 20% Revenue from producing products for licensees and other partners, including legacy and partnered medicines manufactured at Alkermes facilities or through contractors. |
| Royalty revenue | 10% Royalties earned on sales of licensed products that incorporate Alkermes technology, where partners commercialize the medicine and pay usage-based royalties. |
Alkermes sells primarily into the U.S. pharmaceutical channel, where wholesalers, specialty distributors and pharmacies...
Wholesalers, specialty distributors and pharmacies purchase proprietary products for resale and dispensing, making this the core commercial route for ARISTADA, LYBALVI, VIVITROL and LUMRYZ.
Psychiatrists, addiction-treatment providers and public health systems prescribe or administer Alkermes medicines because they address chronic neuropsychiatric and substance-use conditions.
Biopharma partners that commercialize products incorporating Alkermes technology buy manufacturing capacity or generate royalty streams for the company.
Insurers, Medicaid and Medicare Part D programs influence uptake through rebates, formulary access and reimbursement terms, especially for VIVITROL and other branded therapies.
Alkermes is headquartered in Ireland but operates a U.S.-centric commercial model, with its marketed products sold...
Alkermes is focused on growing a neuroscience portfolio built around differentiated commercial products and selective...
Most revenue comes from a concentrated set of branded medicines, so uptake, access and retention are critical to growth.
The company wants to reduce concentration risk and add assets that fit its neuroscience commercial infrastructure.
Product shortages or quality issues could directly reduce sales and damage reputation in regulated pharmaceutical markets.
Alkermes is exposed to concentration risk because a large share of revenue comes from a small number of proprietary...
The company says substantial revenue comes from its key proprietary products, so any decline in demand or access can have an outsized effect on earnings.
Pharmaceutical manufacturing is complex and disruptions in API, quality, equipment, labor or logistics can cause shortages, recalls or lost sales.
Competing branded therapies, generics and alternative treatments can pressure pricing, market share and physician adoption.
LUMRYZ and sodium oxybate are subject to DEA quotas and heightened controls, which can constrain manufacturing and distribution.
Some manufacturing and royalty revenues are earned outside the U.S. and denominated in local currencies, creating translation and transaction risk.
Pharmaceutical Preparations
Avadel Pharmaceuticals plc is a U.S.-based biopharmaceutical company focused on sleep-disorder therapies, with LUMRYZ as its only commercial product.
NBIX · Biological Products, (No Diagnostic Substances)
Neurocrine Biosciences is a U.S.-based biopharmaceutical company focused on neuroscience and related endocrine disorders.
VNDA · Pharmaceutical Preparations
ALNY · Pharmaceutical Preparations
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
ACRS · Pharmaceutical Preparations
Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small and large molecule therapies for immuno-inflammatory diseases.
: 11/08/2026